Schwannomatosis Clinical Trials

Find Schwannomatosis Clinical Trials Near You

Assessment of Patient Experience With Auto-Captioning Glasses in NF2-Related-Schwannomatosis

Status: Recruiting
Location: See location...
Intervention Type: Device
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

The goal of this clinical trial is to investigate the usability of auto-captioning glasses for adults diagnosed with NF2-related schwannomatosis and loss of hearing. The primary objective of the study is to determine the feasibility and acceptability of auto-captioning glasses in this population. Participants will be asked to: * Use the glasses at their discretion for 12 weeks * Report their feedback at 3 and 12 week timepoints via online surveys and remote qualitative interviews

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Diagnosis of NF2-SWN by 2022 revised criteria

• Age 18 years or older at time of consent

• Willing and able to sign informed consent

• Access to a mobile phone with current operating software (i.e., iOS 16+ or Android 12+) and an internet connection

• Does not require prescription glasses to communicate others (e.g. may use reading glasses or similar)

• Resident of the U.S.

• English-speaking

Locations
United States
Massachusetts
Massachusetts General Hospital
RECRUITING
Boston
Contact Information
Primary
David G Bonilla, Sc.B
dbonilla2@mgh.harvard.edu
6319420682
Time Frame
Start Date: 2026-02
Estimated Completion Date: 2026-12
Participants
Target number of participants: 20
Treatments
Experimental: Adults with NF2-SWN and Hearing Loss
Adults with a clinical diagnosis of NF2-SWN and self reported hearing loss will use the auto-captioning glasses for 12 weeks
Related Therapeutic Areas
Sponsors
Leads: Massachusetts General Hospital

This content was sourced from clinicaltrials.gov